ABSTRACT: Intervertebral disc regeneration is quickly moving towards clinical applications. However, it is still missing an ideal injectable hydrogel to support mesenchymal stem cells (MSC) delivery. Herein, a new injectable hydrogel composed of platelet rich plasma (PRP) and hyaluronic acid (HA) blended with batroxobin (BTX) as gelling agent, was designed to generate a clinically relevant cell carrier for disc regeneration. PRP/HA/BTX blend was tested for rheological properties. Amplitude sweep, frequency sweep, and rotational measurements were performed and viscoelastic properties were evaluated. Human MSC encapsulated in PRP/HA/BTX hydrogel were cultured in both growing medium and medium with or without TGF-b1 up to day 21. The amount of glycosaminoglycan was evaluated. Quantitative gene expression evaluation for collagen type II, aggrecan, and Sox 9 was also performed. Rheological tests showed that the hydrogel jellifies in 15 min 20˚C and in 3 min at 37˚C. Biological test showed that MSCs cultured in the hydrogel maintain high cell viability and proliferation. Human MSC within the hydrogel cultured with or without TGF-b1 showed significantly higher GAG production compared to control medium. Moreover, MSCs in the hydrogel underwent differentiation to chondrocyte-like cells with TGF-b1, as shown by histology and gene expression analysis. This novel hydrogel improves viability and proliferation of MSCs supporting the differentiation process toward chondrocyte-like cells. Rheology tests showed optimal gelation kinetics at room temperature for manipulation and faster gelation after transplantation (37˚C). The clinical availability of all components of the hydrogel will allow a rapid translation of this regenerative approach into the clinical scenario. ß
Back pain is strongly associated with intervertebral disc degeneration (IDD). 1 Current treatments for IDD mainly rely on conservative therapies and spinal surgery including fusion, which are only able to relieve the symptoms. These options do not address the cause of the degeneration and may even accelerate the degeneration of adjacent segments. It has prompted research to improve our understanding of the biology of intervertebral disc (IVD) healing and to identify methods to promote the regenerative process. 2 Currently, there are no treatments able to directly reverse the degenerative process involved in IDD. However, there is a strong effort to develop an effective early treatment of IDD that may prevent, slow down, or reverse degenerative changes in the IVD. Recovering the ability of the disc to repair the extracellular matrix re-establishing the proteoglycan content may have a significant therapeutic effect by increasing disc hydration and thereby improving its biomechanics. 2 Adult stem cell therapy may represent a powerful tool in the future treatment of IDD. 3, 4 Transplantation of bone morrow mesenchymal stem cells (MSCs) in a hydrogel carrier can induce regenerative effects in degenerated IVDs in vivo. 5, 6 However, in order to translate this new cell therapy in the medical arsenal, many open questions, such as the most reliable transplantation method including the carrier choice, still need to be addressed. 7 Indeed, cell-based approaches towards restoration of prolapsed or degenerated IVDs are hampered by a lack of measures for safe injection of cell suspensions within a treated disc. 8 Several hydrogels have been used as ideal injectable carriers of cells into the degenerated nucleus pulposus (NP) to promote IVD regeneration. [9] [10] [11] [12] [13] The hydrogel should stimulate the engraftment of MSCs and support their differentiation toward NP cells, promote resident NP cells anabolism as well as active tissue remodelling facilitating the restoration of hydrostatic pressure. Moreover, the success of tissue engineering applications for disc regeneration could be drastically improved with the addition of growth factors that increase the proliferation, differentiation, and recruitment of progenitor or stem cells. 14, 15 Platelet-rich plasma (PRP) has recently emerged as a potential biologic tool to treat acute and chronic disorders in orthopaedics. [16] [17] [18] [19] PRP is a fraction of plasma that contains platelets (PLTs). The regenerative potential of PRP is based on the release of growth factors from the a-granules that occurs with PLTs activation and rupture. In addition, resident cells secret additional biologically active molecules in response to PRP. 20 Moreover, PRP has anti-inflammatory properties through its effects on the canonical nuclear factor kB-signalling pathway in multiple cell types including synoviocytes, macrophages, and chondrocytes. 20 The outcomes of PRP therapy are variable and can include the production of local conditions that favour anabolism, or the recruitment of repairing cells. 20, 21 PRP has been clinically used to accelerate wound healing and tissue regeneration including bone and cartilage in the orthopaedic field. 17, 19 Furthermore, PRP is known to enhance cell viability and matrix metabolism of IVD cells being able to arrest IDD progression in animal models. [22] [23] [24] [25] [26] Hyaluronic acid (HA) has been extensively used as an adjunct in cartilage repair and its use is widespread in clinical practice. 27 It has been one of the first hydrogel to be used as cell carrier for NP regeneration in animal model. 28 Moreover, increasing scientific evidences are showing his biological effects on NP cells. 29 HA and PRP combination for conservative ostheoarthritis (OA) treatment is earning increasing interest supported by the favourable effects as shown in vitro and in vivo in OA models. 30, 31 The clinical availability of these agents allows a direct clinical application of the bland.
Therefore, in this study a new injectable hydrogel cell carrier system composed of PRP and HA blended with batroxobin (BTX) as gelling agent, was designed to generate an ideal clinically relevant carrier to deliver MSCs for IVD regeneration. It was hypothesised that such a system would be a suitable carrier for cells with rheological properties allowing injection and gelation in the disc space supporting cell proliferation and differentiation toward chondrocyte-like cells.
MATERIALS AND METHODS

Scaffold Assembly
PRP Preparation
PLTs were obtained from whole blood healthy volunteer donors after informed consent. PLTs concentrates have been prepared according to the standard procedures for clinical use. One unit of PLTs concentrate was resuspended in 60 ml of plasma and five PLTs units were pooled to obtain 300 ml of PRP containing a PLTs count of 1.8 Â 10 6 cells/ml. Residual white blood cells and red blood cells in PRP were 0.38 Â 10 3 /ml and 0.10 Â 10 3 /ml, respectively. Blood cells count was determined with an automated haematology system according to the pre-analytic recommendations. Total amount of PRP pool was then fractionated in aliquots of 2 ml each, before freezing at À80˚C under controlled temperature. At the end of preparation, sterility testing was performed for each batch of PRP.
The collection, production, and application of blood components for non-transfusional use were carried out using CEmarked devices for the specific purpose, in accordance with Directive 93/42/EC (class II a or higher). PRP growth factors content were performed on 2 ml aliquots using enzyme linked imunosorbent assay (ELISA). The levels of vascular endothelial growth factor (VEGF) was 381,14 pg/ml, platelet derived growth factor (PDGF) was 1,293 ng/ml, and insulin growth factor (IGF) was 164,2 ng/ml.
Hydrogel Assembly HA 1.6%-32 mg/2 ml (Molecular Weight-MW: 800-1200 kDa; Sinovial Forte, IBSA, Switzerland) was mixed with batroxobin (BTX-Plateltex ACT, Plateltex S.R.O, Czech Republic; 5 BU/ml) at 6:1 ratio. BTX has been used as gelling agent, in order to obtain a 3D hydrogel system encapsulating human MSCs in the presence of growth factors. The HA/BTX blend was then mixed at a 1:1 ratio with human PRP. The final concentration of the different components of PRP:HA:BTX ¼ 7:6:1 was chosen for rheological and biological tests. This ratio has been obtained after a preliminary study on gelation of hydrogels obtained using different concentration of HA, PRP, and gelling agents such as BTX or thrombin. The evaluation was conduced using the gelation-tilting test. 32 
Rheological Testing
Rheological measurements were performed using an Anton PaarMCR-302 rheometer equipped with Peltier temperature control device and thermostatic hood. An amplitude sweep at the angular frequency of 10 rad/s was performed before every oscillatory measurement in order to set amplitude within the linear viscoelastic range. Gelation time was evaluated with a 25 mm cone-plate geometry measuring once per minute the viscoelastic shear moduli at 1 Hz at the desired temperature (20 or 37˚C). Gelation time was taken as the first time point displaying storage modulus over loss modulus. For all the other measurements, cone-plate geometry of 50 mm diameter was used; gap was set at 100 mm, correspondent to the cone truncation. Frequency sweep was performed between 0.1 and 100 rad/s; temperature was set at 37.00 AE 0.02˚C. Hydrogels were prepared directly on the bottom element of the rheometer carefully mixing the components. A layer of low-viscosity silicon oil was carefully distributed along the interface meniscus to avoid evaporation throughout the experiment. A waiting time of 10 min was set before frequency sweep measurement in order to allow complete curing.
Biological Testing Human MSCs Isolation and Culture
Bone marrow (BM) aspirates were obtained from healthy subjects, after informed consent was provided, through aspiration of iliac crest using 20 ml syringes preloaded with 500 IU of preservative-free Heparin (PharmaTex Italia, Milano, Italy). Unprocessed BM was directly seeded in alpha Modified Eagle Medium (alpha-MEM, Macopharma, Mouvaux, France) supplemented with 10% high quality gamma irradiated Fetal Bovine Serum (FBS) (Gibco-Life Technologies, Carlsbad, CA), at the concentration of 50,000 total nucleated cells (TNC)/cm 2 in Cell Stack Chamber system (Corning, Lowel, MA). After 72 h, non-adherent cells were removed by washing with PBS (Macopharma) with complete medium change. The culture was daily monitored for the colony appearance. On day 14 þ 7 days, MSC at P0 were detached using 25 ml/layer of TrypLE (TM) Select (Gibco-Life Technologies) and re-seeded in the same culture conditions at the concentration of 4,000 MSCs/cm 2 . The culture was stopped at passage 2 (P2). 
Human MSC and Hydrogel Construct
To obtain a 3D hydrogel construct, human mesenchymal stem cells (MSCs) were suspended in human PRP at the final cell concentration of 5 Â 10 6 cells/ml (component A). HA was mixed with BTX with a ratio of 6:1, (component B). The 3D hydrogel constructs were obtained by mixing 50 ml each of the two components in a 15 ml tube and left to polymerize for 30 min; then a-MEM (Life Technologies, Carlsbad, CA) with 10% fetal bovine serum (FBS-Life Technologies) was added. The final MSCs concentration in the hydrogel was 2,5 Â 10 5 cell/ml.
MSC Viability in the Hydrogel
Viability of human MSCs in the hydrogel blend was assessed using the Live/Dead assay (Life Technologies) after 36 h of culture in growing medium in a 5% CO 2 and 95% air incubator. Briefly, hydrogels were incubated in serum free medium supplemented with 10 mM calcein AM green and 1 mM ethidium homodimer-1 for 30 min. The hydrogels were then placed between a histological slide and a coverslip. Stained samples were visualised on fluorescent Microscope (Nikon Eclipse Tί light microscope, Tokyo, Japan). Red and green cells were counted.
Chondrogenic Differentiation
After 24 h from the construct assembly, three different types of culture media were added to the hydrogel constructs: a-MEM with 10% FBS (control), differentiation media with TGF-b1 33, 34 (Bullet Kit TM , Lonza, Basel, Switzerland with 10 ng/ml TGF-b1 (Peprotech, Rocky Hill, NJ) and differentiation medium without TGF-b1. TGF-b1 is known of one of the key factors necessary to induce chondrogenic differentiation of MSCs derived from bone marrow among the members of the TGF-b family. 35 Media were changed every 3 days for a total of 21 days. Cells were harvested at 7, 14 and 21 days. Cell proliferation was assessed at all time point, while glycosaminoglycan production and gene expression were evaluated only at the last time point.
MSC Proliferation
Cell proliferation was assessed by measuring the DNA content at 1, 7, 14, and 21 days. PicoGreen 1 Assay (Life Technologies) was used to assess MSCs proliferation as per manufacturer's guidelines. A standard curve based on known concentration of DNA was used to determine the DNA content. The sample fluorescence was measured using a microplate reader (Tecan infinite M200 PRO M€ annedorf, Switzerland) at 460 nm and 540 nm, respectively.
Glycosaminoglycan Content
Hydrogel constructs were harvested at 21 days for glycosaminoglycan (GAG) content measurement. Constructs were washed with PBS and digested with 100 ml of papain solution (0.25 mg/ml in 50 mM Phosphate buffer, pH 6.5 containing 5 mM cysteine-hydrochloride and 5 mM EDTA) overnight at 65˚C. Glycosaminoglycans were measured by reaction with 1,9-dimethylmethylene blue (DMMB, Polysciences, Warrington, PA) using chondroitin sulfate (Sigma-Aldrich, St. Louis, MO) as standard. Measurements of absorption were performed at 530 nm (Tecan infinite M200 PRO) and compared to a chondroitin 4-sulfate standard. Total GAG was normalized by the respective DNA content.
Gene Expression
Total RNA was isolated using Trizol Reagent. Briefly samples were put into 1 ml of Trizol and mechanically homogenized using To visualize cell distribution and extracellular matrix accumulation, sections were stained with Alcian Blu (Bio-Optica, Milan, Italy) and Safranin-O (IHC word, LLC, Woodstock, MD) using standard techniques. Images were captured on a Nikon Eclipse Tί light microscope.
Statistical Analysis
For live/dead assay, DNA content, total GAG and gene expression, GraphPad Prism 5 software (GraphPad Software for Science, San Diego, CA) was used for statistical analysis (significance at p < 0.05). One-way analysis of variance (ANOVA) with Tukey post-hoc test was used to determine differences among the different groups. MSCs from three different human donors were used and each experiment was performed in triplicate samples. A p-value <0.05 was considered statistically significant. Figure 1 displays the time dependence of the viscoelastic shear moduli of different hydrogel preparations crosslinked with the same volumetric concentration of BTX. Continuous lines represent storage moduli (G 0 ), dashed lines loss moduli (G 00 ). Black lines represent HA þ PRP at 20˚C; for this formulation the gelation time is 15 min. Red lines represent the same HA þ PRP preparation at 37˚C; in this case the gelation time drops to 3 min. For pure PRP at 37˚C (blue lines) the gel state was achieved in less than one minute. After the gel point, the viscoelastic shear moduli continue to grow asymptotically to their plateaux value.
RESULTS
Rheology Testing
In Figure 1B the mechanical spectrum of the gel prepared from pure PRP is compared to the preparation containing HA. For the pure PRP gel the elastic modulus is circa 0.1 kPa almost independent of the angular frequency. The composite gel including HA is featured by significantly lower storage modulus, and the difference between the storage and loss modulus decreased at higher frequency, almost reaching a crossing point at the angular frequency of 100 rad/s. Figure 2A shows the cultured hydrogel construct 36 h after assembly. Human MSCs viability after 36 h of culture was >90% in the PRP/HA/BTX hydrogel and cells were spread in all material, as shown in Figure 2B .
Biological Testing
MSC Viability
Proliferation of MSC Incorporated in Hydrogel
Proliferation was expressed as the DNA amount of each construct normalized to the DNA at time 0 (t0). MSCs in the hydrogel proliferated overtime in all culture conditions. The proliferation was significantly higher in hydrogels cultured under condition with TGF-b1 compared to the other groups at all-time points (Fig. 3A) .
Differentiation of MSC Incorporated in Hydrogel In Vitro
The MSC encapsulated in PRP/HA/BTX hydrogel cultured with or without TGF-b1 showed significantly higher GAG production compared to control media (Fig. 3B) .
The Alcian Blue/Nuclear Fast Red staining was used to detect the anionic GAG chains of the proteoglycans while Safranin-O staining was performed to confirm proteoglycan content of the matrix produced by cells (Fig. 4A) . MSCs embedded in the PRP/HA/BTX hydrogel underwent differentiation to chondrocyte like-cells with TGF-b1, as shown by the high metachromatic staining of Alcian Blue and the red staining with Safranin-O compared to the other two groups.
Gene expression profiles of MSCs seeded in the PRP/HA/BTX hydrogel cultured in either growing medium or differentiation media were evaluated to determine whether an NP-cell-like gene expression profile could be achieved. At day 21, MSCs seeded in the hydrogel and cultured in both media (with and without TGF) exhibited an up regulation of all genes analysed compared to the cells cultured in control medium (Fig. 4B) . The expression of type II collagen was significantly higher in the construct cultured with TGF-b1 medium compared to the other two. HACAN expression was significantly higher in both groups with and w/out TGF-b1 compared to the control one. Moreover, HACAN level in the TGF-b1 group was significantly higher compared to the group w/out TGF-b1. The gene expression levels of SOX9 were increased only in TGF-b1 group (data not significant).
DISCUSSION
In this study, we evaluated the suitability of a novel PRP/HA/BTX hydrogel as MSC carrier for NP regeneration. Importantly, all materials and technologies used are already clinically approved for the treatment of degenerative and traumatic diseases of the musculoskeletal system. The regulatory clearance of the hydrogel's might allow a rapid translation for clinical right use after in vivo proof of efficacy tests.
PRP is an autologous product derived by whole blood. It is rich in growth factors involved in soft and hard tissue repair. PRP is widely used for the treatment of osteoarthritis in early stages by intra-articular injection with beneficial effects on pain. 17 In the context of disc degeneration, several in vitro studies have shown that growth factors released by PRP induce an up regulation of proteoglycan synthesis and tissue regeneration in disc cells. [22] [23] [24] [25] [26] Moreover, growth factors in PRP comprising TGF-b1, insulin-like growth factor (IGF-I), epidermal growth factors (EGF), and platelet-derived growth factor (PDGF) have also been reported to stimulate (1) cell proliferation, (2) chondrogenic specific genes up regulation, and (3) proteoglycan accumulation of NP cells. 36 Although PRP is used in clinical research, little is known about the potential use in combination with HA and MSCs. Chen et al. 22 investigated the therapeutic effects of HA and PRP for OA treatment. Using an in vitro OA chondrocyte model, these authors showed that the HA and PRP mixture induced chondrogenesis via regenerative signalling associated to an inhibition of the inflammatory pathways. These effects were synergistic compared to either HA or PRP alone.
Moreover, this study showed that HA and PRP effectively recovered symptoms in an OA animal model. Therefore, HA and PRP in a combined treatment are biologically superior compared to their individual use. 30 BTX, which is currently used as PRP activator, acts on fibrinogen, removing fibrinopeptides, hence inducing fibrin polymerization and gelation of PRP. It is a purified enzyme from snake venom. BTX is not a potential inducer of bovine-human cross-reacting antibodies to coagulation factor V and XI, unlike thrombin. 37 It does not affect the PLT function 38 and it is not inhibited by heparin.
39 This is crucial when harvesting precursor cells-containing bone-marrow blood that is usually done using heparin-citrate anticoagulant solution. BTX is able to induce fast gelation of PRP and bone marrow-harvested blood samples being the unique fibrinogen cleaving enzyme. At the same time, it leads a slower and more controlled release of growth factors since PLTs do not activate during the clotting phase. All of these features make BTX biologically superior to thrombin in the production of autologous PLT-gel and clinically effective in medical and surgical practice, which needs well-scheduled working time and maximization of growth factor activity.
HA plays a key role in IVD homeostasis and regeneration. 29, 40 Moreover, the presence of HA within this composite is critical to its rheological properties since it (1) postpones the gelation time of the compound and (2) decreases the gel rigidity. The first feature is ideal for clinical use, since it lets the compound being liquid during preparation, mixing and injection phases achieving gelation at body temperature. Indeed PRP/HA/BTX can be easily handled at 20˚C and rapidly polymerize at 37˚C. The PRP/HA/BTX formulation displayed a gelation time between 2 and 3 min at physiological temperature, which is an ideal timing for the intraoperative use. A shorter crosslinking time would bring the risk of clumping during injection, with difficulty to operate for the surgeon and increased mechanical shear forces potentially detrimental for the cells delivered. Longer time would bring the risk of dislocation of the implanted material before gelation. The temperature displayed a notable effect on the gelation time, which increased to 15 min at 20˚C. This effect can be attributed to the higher mobility of the molecules at higher temperature, and the improved enzymatic activity. Pure PRP polymerized with the same volumetric concentration of BTX (i.e., one half of the PRP/BTX ratio compared to the standard gel) has an extremely short gelation time, curing already during the sample preparation interval. Therefore, HA acts as retardant for the crosslinking of the system, increasing the gelation time to values of 2-3 min, that is, a range suitable for the intended use. The second consequence of the HA addition is related to crosslinking density and gel rigidity. After gelation, viscoelastic shear moduli increases with a progressively lower gradient, reaching a plateau with no further drifting. The mechanical spectra of the gels prepared in presence and absence of HA show significant differences. Pure PRP gel shows a higher storage modulus, almost independent of the angular frequency while for the HA-PRP gel the storage modulus is about one order of magnitude lower, with more pronounced frequency dependence. The profile is indicative of a less densely packed and less rigid molecular network in presence of HA. Both features are convenient to use the gel for the delivery of living cells. Indeed, excessive gel rigidity is known to impede cell proliferation, differentiation, and matrix synthesis. 41 The signalling pathway triggered by TGF-b family involving the transcription SOX9. The activation of this pathway leads to the induction of structural extracellular matrix proteins such as collagen type II and aggrecan leading to the accumulation of extracellular matrix GAGs. In this study, the use of MSCs encapsulated in a hydrogel composed of HA and PRP, determine a switch with the expression of chondrocyte-like differentiation markers. The growth factors from PRP incorporated in the hydrogel alone, including TGF-b1, were not able to induce such differentiation. TGF-b1 was required to enhance the potential of chondrogenic differentiation. This is probably due to the short half-life of the PRP growth factors that were active, most probably, only during the first few days of culture. However, in the in vivo scenario the anabolic growth factors released by PRP contained in the carrier might support MSCs for the period of the intradiscal engraftment, overcoming the cellular stress arising from the new environment, such low pH, low oxygen partial pressure and low nutrition.
A crucial result of this study is that the hydrogel support cells viability until the end of the 21 days of the experiment, demonstrating that the composition of scaffold is not cytotoxic.
The originality of this study consist in combining clinically available biomaterials, blood derivate and drugs to obtain an effective hydrogel to support MSCs injection for IVD regeneration. This might move forward cell therapy to the translation from bench to bedside. Ongoing ex vivo tests in a bioreactor system 42, 43 and an in vivo study in an animal model 44, 45 will provide more evidences for IVD regeneration mediated by the transplanted MSCs in combination with the novel hydrogel.
CONCLUSIONS
This study demonstrated that a novel hydrogel composed by PRP/HA/BTX maintain cell viability and allow proliferation of MSCs promoting and supporting the differentiation process toward chondrocyte likecells. Rheology tests showed optimal gelation kinetics at room temperature for hydrogel manipulation and faster gelation after implantation at body temperature. Moreover, the polymerized hydrogel give rise to a molecular network, which is friendly to cell proliferation, differentiation, and matrix synthesis, pivotal processes for the repair of connective tissues. 41 The clinical availability and regulatory clearance of all components of the hydrogel allows a rapid translation of the proposed regenerative approach to the clinical scenario.
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